Research & Development

At PRI, we are engaged in three key areas of Research & Development:

  • Drug Discovery at PRI reaches across therapeutic areas: hematology, oncology, cardiovascular, ophthalmology, vascular diseases, neurology, and inflammation.
  • Drug Development at PRI includes drug formulation (particularly nanoformulation) and stability testing, leading to clinical trials.
  • Nanotechnology/Biotechnology at PRI covers a wide range of applications. An example PRI’s nanobiotechnology approach is targeted delivery of nanoparticles loaded with chemotherapeutic agents for pancreatic, brain, breast, prostate, ovarian, and lung cancer.
For more additional information on our work in these areas, expand the sections below or visit our Publications Page.

Drug Discovery
PRI focuses on in vitro and in vivo models of disease across multiple therapeutic areas, described here.


  • Angiogenesis modulation
  • Thrombosis (Coagulation/platelet)
  • Cancer biology

Cardiovascular (Dyslipidemia)

  •  LDL-C lowering targets
  • HDL-C raising targets
  • Preclinical models of dyslipidemia
  • Targeted delivery

Vascular Diseases

  • Peripheral Artery Disease
    • Cell therapy
    • Pharmacotherapy
    • Combination therapy
  • Cardiovascular Diseases
    • Acute Coronary Syndrome
  • Cerebrovascular Diseases
    • Stroke


  • Downregulation of pathological angiogenesis (retina and choroidal neovascularization) in diabetic retinopathy and macular degeneration
  • Ocular delivery of angiogenesis modulators


  • Pain modulation in cancer, inflammatory, and other disorders
  • Nano-targeted delivery across the blood-brain barrier


  • Development of novel anti-inflammatory targets including NFκB and other pathways in various acute and chronic inflammatory disorders
Drug Development
PRI focuses on stability testing and drug formulation leading to clinical trials, with the potential of discovering new strategies to treat current and emerging disease states.

Stability Testing

  • In vitro evaluation of stability and release properties for formulations

Formulation and Drug Delivery

  • Reformulation of existing drugs to improve their PK/PD (efficacy) and safety
  • Formulation to enhance drug solubility, improve bioavailability, enhance drug stability, target tissue delivery, and treat specific patient populations


  • Develop targeted drug delivery using nanotechnology and nanoformulations to target specific organ(s) with a payload of active drug to be delivered to site of action

Clinical Monitoring – PK/PD (Phase I – Phase IV)

  • Develop and validate analytical biomarkers and bioassays for PK/PD monitoring


  • Developed and patented a novel device for the removal of chemotherapy or other agent(s) after its local delivery to the target organ
We are harnessing the versatility of nanotechnology and biotechnology (sometimes called nanobiotechnology) in formulating nanoparticles that can be targeted directly to a tumor site or other specific organ within the body and carry a payload of potent drug molecule(s) for treatment.

Nanobiotechnology for Early Detection and Treatment

  • Early detection of different tumor types using nanotechnology-based imaging techniques
  • Targeted delivery of chemotherapeutic agent-loaded nanoparticles for pancreatic, brain, breast, prostate, ovarian, lung, and other cancer types
  • Nano-encapsulation of various natural products for improved pharmacokinetics and pharmacodynamics
  • Conjugation of different targeting agents on nanoparticles’ surface to improve efficacy and safety, for example nanoparticle thyroid agonists and antagonists
  • Nano-targeted delivery to cancer cells and associated cancer stem cells

PRI Drug Discovery Areas Using Nanobiotechnology Platforms

  • Cardiovascular and Vascular diseases
    • Regional Atherothrombosis Working Group (ACPHS, AMC, SUNY Nano Sciences, RPI, Wadsworth, and VA at Albany) in Atherosclerosis/Thrombosis toward the establishment of Center for Innovation in the early detection, prevention, and treatment of Atherothrombosis
  • Ophthalmology-related disorders
    • Development of novel angiogenesis inhibitors for the suppression of retinal and choroidal neovascularization for the treatment of diabetic retinopathy and age-related macular degeneration
  • Oncology and Hematological disorders
  • Inflammatory diseases
    • Development of novel therapy for acute and chronic inflammatory disorders
  • Neurological disorders
    • Targeted delivery of novel target for neurological disorders

PRI Drug Development Areas Using Nanobiotechnology Platforms

  • Nanoformulation and Drug Delivery
    • Reformulation of existing generic pharmaceuticals
    • Nanoformulation of new drug targets